Closing Chasms and Optimizing Care in Hereditary Hemorrhagic Telangiectasia: Expert Perspectives on the Role of Intravenous Iron in the Management of HHT-Associated IDA

To take the post-test and claim your CE credit for this session, please visit: https://online.epocrates.com/contextuallink/cme/activity/OQUMHWThis educational initiative is targeted to the community-based multidisciplinary and interprofessional HHT treatment team of primary care physicians, internists, hematologists, oncologists, gastroenterologists, otorhinolaryngologists, allergists, and nurses/nurse practitioners, pharmacists, and physician assistants. Strategically developed to promote community clinician awareness of HHT and galvanize optimization of HHT-associated ID and IDA management, this episode will begin with an overview of HHT epidemiology and pathophysiology, emphasizing diverse disease manifestations and clinical presentation, then move into an appraisal of current guideline recommendations for diagnosing, screening, and treating HHT-associated IDA, with an incisive focus on the role of intravenous (IV) iron as iron replacement therapy. Practical differentiators between currently-available IV iron products, inclusive of total dose infusion (TDI) capacity and relative risk for IV iron-induced hypophosphatemia, will be highlighted and emphasized throughout the activity using practical patient case scenarios.